Skip to main content
Premium Trial:

Request an Annual Quote

MDS Proteomics Signs Five-Year Deal with Cephalon

NEW YORK, Jan. 7-MDS Proteomics and Cephalon have struck a five-year joint drug development agreement, the two companies said today.

 

Under the agreement, MDS Proteomics will supply various proteomics technologies, including chemiproteomics, phosphorylation fingerprinting and protein interaction mapping, in order to improve clinical development of Cephalon's candidate compounds for central nervous system disease.

 

In return, MDS Proteomics will receive milestone payments and royalties on product sales. Cephalon has also purchased a $30 million 5 percent convertible note from MDS Proteomics. The note, which is due in 2010, is convertible into MDS Proteomics common stock at $22 per share.

 

MDS Proteomics is a privately held systems biology company based in Toronto.

 

Cephalon, a publicly held drug development firm, is headquartered in West Chester, Pa.

 

 

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.